HER2阳性乳腺癌疗效相关生物标志物研究进展

Research progress of biomarkers related to the efficacy of HER2 positive breast cancer

目前,乳腺癌是最常见的癌症,也是全世界女性癌症死亡的主要原因。其中,人表皮生长因子受体2(HER2)阳性乳腺癌约占所有乳腺癌的15%,此亚型乳腺癌具有高侵袭性且预后差的特点。随着抗HER2靶向药物的兴起,该亚型患者的预后得到了极大的改善。然而,还是有部分患者对靶向药物的反应不佳,因此,挑选出能够预测治疗效果的生物标志物对于改善这部分患者的疗效起着至关重要的作用。本文阐述了HER2阳性乳腺癌生物标志物,聚焦有关靶向治疗疗效的生物标志物的研究进展,希望为临床优化靶向治疗方案提供一些参考思路和线索。

Breast cancer is the most commonly diagnosed cancer and the main cause of cancer deaths among women worldwide.HER2 positive breast cancer accounts for 15%of all breast cancer.This subtype of breast cancer is highly invasive and has a very poor prognosis.With the development of anti-HER2 targeted therapy,the prognosis of these patients has been improved.However,some patients have poor response to the anti-HER2 therapy.Therefore,it is necessary to select biomarkers that can predict the therapeutic effect for improving the efficacy of these patients.This article describes the research progress of HER2 positive biomarkers for breast cancer,focusing on biomarkers related to the efficacy of targeted therapy,in order to provide some reference for future clinical optimization of targeted therapy.